X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azd4547 (57) 57
index medicus (44) 44
humans (37) 37
cancer (31) 31
oncology (29) 29
gene amplification (17) 17
fibroblast growth factors (15) 15
expression (14) 14
cell line, tumor (13) 13
fgfr (12) 12
selective inhibitor (12) 12
animals (11) 11
antineoplastic agents - pharmacology (11) 11
cell proliferation - drug effects (11) 11
fibroblasts (11) 11
growth factors (11) 11
protein kinase inhibitors - pharmacology (11) 11
biochemistry & molecular biology (10) 10
fibroblast growth factor receptors (10) 10
gene expression (10) 10
kinases (10) 10
mutation (10) 10
mutations (10) 10
receptors, fibroblast growth factor - antagonists & inhibitors (10) 10
cell biology (9) 9
female (9) 9
fibroblast growth factor (9) 9
fibroblast growth factor receptor (9) 9
gastric cancer (9) 9
growth (9) 9
health aspects (9) 9
male (9) 9
potent (9) 9
pyrazoles - pharmacology (9) 9
receptor, fibroblast growth factor, type 1 - genetics (9) 9
receptor, fibroblast growth factor, type 1 - metabolism (9) 9
amplification (8) 8
benzamides - pharmacology (8) 8
carcinoma (8) 8
care and treatment (8) 8
chemistry, medicinal (8) 8
inhibitor (8) 8
piperazines - pharmacology (8) 8
sensitivity (8) 8
activation (7) 7
analysis (7) 7
article (7) 7
breast cancer (7) 7
development and progression (7) 7
fgfr1 (7) 7
lung cancer (7) 7
metastasis (7) 7
mice (7) 7
middle aged (7) 7
molecular structure (7) 7
receptor, fibroblast growth factor, type 2 - metabolism (7) 7
tumors (7) 7
tyrosine (7) 7
aged (6) 6
angiogenesis (6) 6
antineoplastic agents - chemistry (6) 6
apoptosis (6) 6
cancer therapies (6) 6
carcinoma, squamous cell - genetics (6) 6
chemotherapy (6) 6
dose-response relationship, drug (6) 6
family (6) 6
inhibitors (6) 6
lung neoplasms - drug therapy (6) 6
lung neoplasms - genetics (6) 6
medicine & public health (6) 6
protein kinase inhibitors - chemistry (6) 6
receptor, fibroblast growth factor, type 1 - antagonists & inhibitors (6) 6
stomach cancer (6) 6
studies (6) 6
tyrosine kinase (6) 6
xenograft model antitumor assays (6) 6
antineoplastic agents - therapeutic use (5) 5
cell proliferation (5) 5
cells (5) 5
drug resistance (5) 5
drug screening assays, antitumor (5) 5
fgfr2 (5) 5
fibroblast growth factor receptor 1 (5) 5
genetic aspects (5) 5
growth-factor receptor (5) 5
in situ hybridization, fluorescence (5) 5
inhibitor azd4547 (5) 5
phosphorylation (5) 5
ponatinib (5) 5
proteins (5) 5
receptor, fibroblast growth factor, type 2 - antagonists & inhibitors (5) 5
receptor, fibroblast growth factor, type 2 - genetics (5) 5
receptors, fibroblast growth factor - metabolism (5) 5
research (5) 5
resistance (5) 5
selectivity (5) 5
signal transduction (5) 5
signal transduction - drug effects (5) 5
structure-activity relationship (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Oncology, ISSN 1574-7891, 06/2018, Volume 12, Issue 7, pp. 993 - 1003
Although regorafenib has demonstrated survival benefits in patients with metastatic colorectal and gastrointestinal stromal tumors, no proven biomarker has... 
FGFR2 amplification | colorectal cancer | regorafenib | gastric cancer | MULTICENTER | SOLID TUMORS | ANTITUMOR-ACTIVITY | BAY 73-4506 | HEPATOCELLULAR-CARCINOMA | TARGETED THERAPIES | INHIBITOR AZD4547 | ONCOLOGY | GROWTH | PHASE-3 TRIAL | GENE AMPLIFICATION
Journal Article
Journal Article
Virchows Archiv, ISSN 0945-6317, 2/2014, Volume 464, Issue 2, pp. 145 - 156
Journal Article
Oncogene, ISSN 0950-9232, 07/2016, Volume 35, Issue 27, pp. 3587 - 3597
Targeted therapies are effective in subsets of lung cancers with EGFR mutations and anaplastic lymphoma kinase (ALK) translocations. Large-scale genomics have... 
ACTIVATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | IN-SITU HYBRIDIZATION | ACQUIRED-RESISTANCE | SENSITIVITY | CELL BIOLOGY | BREAST-CANCER | AZD4547 | TARGETED THERAPIES | GENOMICS | ONCOLOGY | GROWTH | GENETICS & HEREDITY | GENE AMPLIFICATION | Lung Neoplasms - drug therapy | Receptor, ErbB-2 - genetics | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Immunoblotting | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors | Receptors, Fibroblast Growth Factor - genetics | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Pyrazoles - pharmacology | Lung Neoplasms - genetics | Cell Line | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Imatinib Mesylate - pharmacology | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | In Situ Hybridization, Fluorescence | Gene Dosage | Signal Transduction - genetics | Pyrimidines - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Piperazines - pharmacology | Xenograft Model Antitumor Assays | Carcinoma, Squamous Cell - drug therapy | Gene Amplification | Signal Transduction - drug effects | Receptor, Platelet-Derived Growth Factor alpha - genetics | Receptors, Fibroblast Growth Factor - metabolism | Cell Line, Tumor | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Molecular targeted therapy | Care and treatment | Lung cancer | Innovations | Development and progression | Genetic aspects | Gene expression | Health aspects | Phosphotransferases | Fibroblast growth factor receptors | Epidermal growth factor | Biomarkers | Lymphomas | Mutation | Cancer therapies | Tumors
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 07/2017, Volume 135, pp. 531 - 543
A series of 2-oxo-3, 4-dihydropyrimido[4,5- ]-pyrimidinyl derivatives were designed and synthesized as new irreversible inhibitors of the FGFR family. One of... 
FGFR | Irreversible inhibitor | 2-Oxo-3,4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives | CHEMISTRY, MEDICINAL | DISCOVERY | FAMILY | AZD4547 | 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives | SELECTIVE INHIBITOR | POTENT | PATHWAY | REACTIVATION | RESISTANCE | TYROSINE KINASE INHIBITOR | TARGETING FGFR | Cell Line | Protein Kinase Inhibitors - chemical synthesis | Receptor, Fibroblast Growth Factor, Type 4 - metabolism | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Pyrimidines - chemical synthesis | Antineoplastic Agents - chemical synthesis | Humans | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | Structure-Activity Relationship | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 3 - metabolism | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Molecular Structure | Protein Kinase Inhibitors - pharmacology | Receptor, Fibroblast Growth Factor, Type 4 - antagonists & inhibitors | Drug Screening Assays, Antitumor | Fibroblast growth factors | Enzyme inhibitors | Drug discovery | Lung cancer, Non-small cell | Derivatives (Financial instruments) | Resveratrol
Journal Article
Oncogene, ISSN 0950-9232, 06/2016, Volume 35, Issue 22, pp. 2852 - 2861
Osteosarcoma is the most common primary malignancy of the skeleton and is prevalent in children and adolescents. Survival rates are poor and have remained... 
BIOCHEMISTRY & MOLECULAR BIOLOGY | GROWTH-FACTOR RECEPTORS | C-FOS PROTOONCOGENE | CANCER | NUCLEAR TRANSLOCATION | CELL BIOLOGY | OVEREXPRESSION | ONCOLOGY | OSTEOBLASTS | GENETICS & HEREDITY | GENE-EXPRESSION | BONE | DIFFERENTIATION | TRANSGENIC MICE | Humans | Transcriptional Activation | Colon - drug effects | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Male | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Transcription Factor AP-1 - metabolism | Chondrocytes - drug effects | Receptor, Fibroblast Growth Factor, Type 1 - deficiency | Lung Neoplasms - secondary | Chondrosarcoma - genetics | Chondrosarcoma - pathology | Gene Expression Regulation, Neoplastic - drug effects | Chondrocytes - pathology | Oncogenes - genetics | Colon - pathology | Osteoblasts - drug effects | Gene Silencing | Proto-Oncogene Proteins c-fos - metabolism | Fibroblast Growth Factors - pharmacology | Enzyme Activation - drug effects | Osteoblasts - pathology | Animals | Signal Transduction - drug effects | Cell Line, Tumor | Proto-Oncogene Proteins c-fos - genetics | Cell Proliferation - drug effects | Mice | Osteosarcoma - genetics | Osteoblasts - metabolism | Osteosarcoma - pathology | Mitogen-Activated Protein Kinases - metabolism | Complications and side effects | Osteosarcoma | Lung cancer | Development and progression | Genetic aspects | Cellular signal transduction | Metastasis | Gene expression | Health aspects | Fibroblast growth factor receptors | Physiological aspects | Research | Protein kinases | Bone cancer | AZD4547 | metastasis | tyrosine kinase | c-Fos | AP-1 | FGFR | osteosarcoma
Journal Article
Journal Article
36.